Navigation Links
Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:1/23/2008

preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and quarterly report on Form 10-Q for the quarter ended July 31, 2007. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Barbara Lindheim

(800) 987-8256 (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
3. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
4. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
5. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation ... to support older adults suffering from the severe ... AARP and its members are committed to helping those ... AARP and AARP Foundation will match dollar-for-dollar contributions up ... aid. The matching program will be administered through AARP ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion ... today announced that it has received commitments from ... $15 million of the Company,s common stock in ... dedicated health care fund. The Company ... pursuant to which the Company agreed to sell ...
(Date:1/15/2014)... 15, 2014 Shire plc (LSE: SHP, ... the Office of Fair Trading (OFT) approval condition to the ... ViroPharma Incorporated (NASDAQ: VPHM).   As a result ... OFT approval, and Shire expects to complete the tender offer ... subject to the satisfaction of all of the remaining conditions ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... 2011 PDI, Inc. (Nasdaq: PDII ), a ... companies, today announced the extension of a contract sales engagement ... began April 1 and will run for the balance of ... PDI of approximately $23 million. Under the program, ...
... April 4, 2011 VIVUS, Inc. (Nasdaq: VVUS ... the investigational drug QNEXA® for two years showed reductions in ... as improvements in lipid levels following significant reductions in weight ... two years. The data – additional results ...
Cached Medicine Technology:PDI Announces Contract Extension With Revenue Value of Approximately $23 Million 2Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits 2Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits 3
(Date:4/14/2014)... A new study identifies a molecule that is a ... the molecule could be an important target for colorectal ... , The study of microRNA-135b (miR-135b) in two animal ... Cancer Cell and was led by researchers ... Arthur G. James Cancer Hospital and Richard J. Solove ...
(Date:4/14/2014)... 14In dense, urban centers around the world, many people ... by tall buildings that block sunlight. And as the ... closer together, the darkness will only spread. , ... corrugated, translucent panel that redirects sunlight onto narrow streets ... hung over the edge at an angle, where it ...
(Date:4/14/2014)... Using antibiotics alone to treat children with uncomplicated acute ... to less pain and fewer missed school days, according ... team at Nationwide Children,s Hospital and published online April ... of Surgeons , is the first prospective study on ... the United States. , Researchers enrolled 77 patients ...
(Date:4/14/2014)... it comes to the cost and quality of hospital ... best care when they are treated in units that ... their current job, according to a study from researchers ... School. The study was published in the current issue ... , The review of more than 900,000 patient ...
(Date:4/11/2014)... insights into the processes that control brain cell production ... and other brain-related disorders. , Scientists have gained new ... that controls how and when nerve and brain cells ... to develop and keeps it healthy. Their findings could ... of control, which is a fundamental characteristic of many ...
Breaking Medicine News(10 mins):Health News:Study identifies a likely key driver of colorectal cancer development and progression 2Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2
... ... ... ... ...
... ... CyberKnife patients in February 2010, , ... Chicago (PRWEB) February 22, 2010 -- Accelitech LLC ... New Brunswick, NJ, a hospital-based facility operated by Saint Peter’s University Hospital. The ...
... ... ... , ... AAPA honors U.S. Surgeon General Regina Benjamin for commitment to patient care , ...
... ... of the RDX storage technology include industry leaders Dell, Fujitsu, Hitachi, HP, IBM, Imation, Maxell, ... ... announced that Maxell , a technology and marketing leader in premium data storage media ...
... ... proudly offer lead commission on submitted and completed applications as well as multiple tiers of ... advertising partner today and start earning some of the highest affiliate commissions in the financial ... Orem, UT ...
... ... create an opportunity for millions of PowerPoint and Keynote users to up their game ... Santa Clara, ... Ed Kaim unveiled SpeakFlow™, a suite of tools for creating, managing, and delivering non-linear ...
Cached Medicine News:Health News:AppDynamics Announces General Availability of AppDynamics v2.0 2Health News:AppDynamics Announces General Availability of AppDynamics v2.0 3Health News:AppDynamics Announces General Availability of AppDynamics v2.0 4Health News:AppDynamics Announces General Availability of AppDynamics v2.0 5Health News:AppDynamics Announces General Availability of AppDynamics v2.0 6Health News:AppDynamics Announces General Availability of AppDynamics v2.0 7Health News:AppDynamics Announces General Availability of AppDynamics v2.0 8Health News:AppDynamics Announces General Availability of AppDynamics v2.0 9Health News:Accelitech's 2nd New Jersey CyberKnife Site Commences Operations 2Health News:Physician Assistants Call on Congress for Policies That Promote High-Quality Patient Care 2Health News:Physician Assistants Call on Congress for Policies That Promote High-Quality Patient Care 3Health News:Maxell Joins RDX Storage Alliance to Support Growing Storage Professionals' Community 2Health News:Maxell Joins RDX Storage Alliance to Support Growing Storage Professionals' Community 3Health News:Check City Announces New Payday Affiliate Campaign Through Partnership With The Share A Sale Affiliate Network 2Health News:Check City Announces New Payday Affiliate Campaign Through Partnership With The Share A Sale Affiliate Network 3Health News:SharpLogic Announces Launch Of SpeakFlow Non-Linear Presentation Suite At SpeakFlow.com 2Health News:SharpLogic Announces Launch Of SpeakFlow Non-Linear Presentation Suite At SpeakFlow.com 3
... insulin pen with a memory. HumaPen MEMOIR records the ... (including priming doses). You can see exactly when and ... you simply "dial" your dose by turning the dose ... initial set-up. If you dial too many units, you ...
Assay development using client's antibodies and antigens to meet diagnostic target...
Colloidal Gold Conjugated, Streptavidin - 50 OD...
Colloidal Gold Conjugated, Goat anti-rabbit IgG (H&L) - 50 OD...
Medicine Products: